GPR132 and acute myeloid leukemia: Treatment with 8GL also significantly increased the frequency of CD11b+ differentiated AML cells (Fig. 7E), and a decrease in blast cell number (Fig. 7F), indicating that the activation of GPR132 by agonizts (such as 8GL) may serve as a potent therapeutic strategy for the treatment of AML.